(Q33391857)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20839030%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20839030%20AND%20SRC:MED&resulttype=core&format=json

multicenter clinical trial

13 February 2020

main subject

phase II clinical trial

0 references

0 references

author

Tony Mok

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20839030%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Michael J. Boyer

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20839030%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Anna K. Nowak

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20839030%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

9

Henry C Pitot

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20839030%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

14

Charles Erlichman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20839030%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

2

Michelle R Mahoney

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20839030%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

10

Joseph Rubin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20839030%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1

George P Kim

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20839030%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

6

Kyle Holen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20839030%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

7

Joel Picus

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20839030%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

Daniel Szydlo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20839030%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Robert Marshke

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20839030%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Philip A Philip

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20839030%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

John J Wright

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20839030%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

publication date

14 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20839030%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

13 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20839030%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20839030%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20839030%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

387-394

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20839030%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10637-010-9532-1

13 February 2020

exact match

0 references

cites work

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896232

Sorafenib in advanced hepatocellular carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896232

Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896232

The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896232

Global cancer statistics, 2002

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896232

Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896232

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896232

Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896232

Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896232

Ubiquitin-mediated proteolysis: biological regulation via destruction

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896232

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896232

Genetic aspects of hepatocellular carcinogenesis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896232

Transcriptional repression of p53 promoter by hepatitis C virus core protein

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896232

The ubiquitin-mediated proteolytic pathway as a therapeutic area

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896232

Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896232

Optimal two-stage designs for phase II clinical trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896232

Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome

21 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9532-1

A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9532-1

A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9532-1

PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9532-1

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9532-1

Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896232

The proteasome inhibitor PS-341 in cancer therapy.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896232

Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse

31 October 2018

1 reference

12 December 2020

Epidemiology of hepatocellular carcinoma in USA

1 reference

12 December 2020

Rising incidence of hepatocellular carcinoma in the United States

1 reference

12 December 2020

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

12 December 2020

10.1007/S10637-010-9532-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20839030%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

13 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20839030%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference